Proliferating Cell Nuclear Antigen Expression to Predict Occult Disease in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors
- 1 October 1994
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 152 (4) , 1133-1138
- https://doi.org/10.1016/s0022-5347(17)32522-3
Abstract
We analyzed primary tumor tissue from 89 clinical stage I nonseminomatous germ cell testicular tumor patients for proliferating cell nuclear antigen expression and histological features to determine if these elements could distinguish pathological stage I (52 patients) from pathological stage II disease or patients who later had relapse (37). Using a monoclonal antibody (PC10) developed for use in archival tissue, nuclear proliferating cell nuclear antigen expression was immunohistochemically measured for the overall tumor (total proliferating cell nuclear antigen) and for each neoplastic cell type present. In addition, the primary tumor was examined for the presence of vascular invasion and determination of the percentage of tumor composed of embryonal carcinoma. Univariate logistic regression analysis revealed higher total (p = 0.0001) and higher embryonal carcinoma proliferating cell nuclear antigen expression (p = 0.0437) to be statistically significant risk factors for occult disease, correctly predicting its presence 73% and 61.5% of the time, respectively. More importantly, the presence of vascular invasion and a higher percentage embryonal carcinoma were highly significant risk factors for occult disease and were truly predictive in 80.4% and 77.2% of the cases, respectively. Multivariate logistic regression analysis revealed a combination of vascular invasion and percentage embryonal carcinoma to be the best model to predict occult disease correctly (85.9%). The addition of total or embryonal carcinoma proliferating cell nuclear antigen expression did not improve the clinical use of the model containing vascular invasion and percentage embryonal carcinoma. Although proliferating cell nuclear antigen expression mirrors the biological behavior of clinical stage I nonseminomatous germ cell testicular tumor to some degree, assessment of vascular invasion and percentage embryonal carcinoma has greater clinical use.Keywords
This publication has 37 references indexed in Scilit:
- Retroperitoneal Lymphadenectomy for Clinical Stage a Testis Cancer (1965 to 1989): Modifications of Technique and Impact on EjaculationJournal of Urology, 1993
- Staging Relationships and Outcome in Early Stage Testicular Cancer: A Report From the Testicular Cancer Intergroup StudyJournal of Urology, 1991
- Treatment of testicular cancer: a new and improved model.Journal of Clinical Oncology, 1990
- Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites.The Journal of cell biology, 1987
- Cyclin (PCNA, auxiliary protein of DNA polymerase δ) is a central component of the pathway(s) leading to DNA replication and cell divisionFEBS Letters, 1987
- Increased nuclear cyclin/PCNA antigen staining of non S‐phase transformed human amnion cells engaged in nucleotide excision DNA repairFEBS Letters, 1986
- Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycleExperimental Cell Research, 1986
- Immunochemical and biochemical analysis of the proliferating cell nuclear antigen (PCNA) in HeLa cellsExperimental Cell Research, 1986
- Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase.Proceedings of the National Academy of Sciences, 1985
- ORCHIDECTOMY ALONE IN TESTICULAR STAGE I NON-SEMINOMATOUS GERM-CELL TUMOURSThe Lancet, 1982